RecruitingPhase 2NCT06052618
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Studying Castleman disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramya M Ramaswami, M.D.National Cancer Institute (NCI)
- Intervention
- Pacritinib(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2025 – 2034
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06052618 on ClinicalTrials.govOther trials for Castleman disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07085039Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman DiseaseUniversity of Pennsylvania
- RECRUITINGPHASE2NCT05907759Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNational Cancer Institute (NCI)
- RECRUITINGNCT06720870An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life ContextIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT05081141HHV8 and Solid Organ TransplantationFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- ACTIVE NOT RECRUITINGPHASE2NCT03933904Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseUniversity of Pennsylvania
- RECRUITINGNCT03300830Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseNational Cancer Institute (NCI)
- RECRUITINGNCT02817997International Registry for Patients With Castleman DiseaseUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT01552434Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer Center